WEDNESDAY, Nov. 27, 2024 (HealthDay News) — The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the risk of diabetes in obese prediabetic patients by more than 90% during a three-year period compared to placebo, trial resultsContinue Reading

TUESDAY, Nov. 26, 2024 (HealthDay News) — The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid. However, the move would have to be approved by the new Trump administration.  Right now, a law passed byContinue Reading

FRIDAY, Nov. 22, 2024 (HealthDay News) — How long Americans can expect to live varies dramatically — and the gap continues to widen. A new report says health inequalities have, in essence, created 10 Americas. These mutually exclusive populations are divided along familiar fault lines, including race, ethnicity, income andContinue Reading

FRIDAY, Nov. 22, 2024 (HealthDay News) — America’s kitchen trash bins are receiving more unwanted food as appetites falter among people taking GLP-1 weight-loss meds, a new study shows. GLP-1s like Ozempic, Wegovy, Mounjaro and Zepbound all work by making food less desirable, and it’s showing up in more foodContinue Reading